Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

Apogee Therapeutics (NASDAQ: APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Novocure stock surged after the Food and Drug Administration approved its Optune Pax product, which delivers tumor treating ...

On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors ...

Investing.com -- Moleculin Biotech Inc (NASDAQ:MBRX) stock rose 3.1% in premarket trading Wednesday after the company reported encouraging preliminary data from its ongoing pivotal Phase 2B/3 "MIRACLE ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Rhythm Pharmaceuticals (NASDAQ: RYTM) is another biotech stock (in this case, a mid-cap stock) that I think could easily ...

Investing.com -- Sana Biotechnology Inc (NASDAQ:SANA) stock fell 2.2% on Tuesday after the cell engineering company announced the appointment of Brian Piper as its new Executive Vice President and ...